/images/ppid_59c68470-image-177104502841632289.webp)
What is the story about?
Hyderabad-based Natco Pharma has received approval from the Central Drugs Standard Control Organisation (CDSCO) to manufacture and market generic semaglutide injection in India.
The company said in an exchange filing that it plans to launch the product in the Indian market in March 2026.
Semaglutide is indicated for the treatment of adults with inadequately controlled type 2 diabetes mellitus, as an adjunct to diet and exercise.
Natco Pharma had earlier filed a suit before the Delhi High Court seeking revocation of Danish drugmaker Novo Nordisk's patent over semaglutide.
Separately, Dr Reddy's Laboratories had also approached the Delhi High Court last year under provisions of the Patents Act and the Commercial Courts Act, seeking revocation of Indian Patent No. IN 262697 granted to Novo Nordisk.
Shares of Natco Pharma Ltd. settled 2.13% lower on Friday at ₹822. The stock is down 8% on a year-to-date basis.
The company said in an exchange filing that it plans to launch the product in the Indian market in March 2026.
Semaglutide is indicated for the treatment of adults with inadequately controlled type 2 diabetes mellitus, as an adjunct to diet and exercise.
Natco Pharma had earlier filed a suit before the Delhi High Court seeking revocation of Danish drugmaker Novo Nordisk's patent over semaglutide.
Separately, Dr Reddy's Laboratories had also approached the Delhi High Court last year under provisions of the Patents Act and the Commercial Courts Act, seeking revocation of Indian Patent No. IN 262697 granted to Novo Nordisk.
Shares of Natco Pharma Ltd. settled 2.13% lower on Friday at ₹822. The stock is down 8% on a year-to-date basis.
/images/ppid_a911dc6a-image-177099005591672127.webp)
